1 / 5

FY15 – FY19 STRATEGIC PLAN PROGRESS REPORT

FY15 – FY19 STRATEGIC PLAN PROGRESS REPORT. 3. 1. 2. ACCELERATE. Accelerate discovery to cure psoriatic disease. IMPROVE. Dramatically improve health outcomes for all with psoriatic disease. SECURE. Secure resources to achieve the mission. GOAL 1 - ACCELERATE DISCOVERY. 1.

psteffen
Download Presentation

FY15 – FY19 STRATEGIC PLAN PROGRESS REPORT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FY15 – FY19 STRATEGIC PLAN PROGRESS REPORT 3 1 2 ACCELERATE Accelerate discovery to cure psoriatic disease IMPROVE Dramatically improve health outcomes for all with psoriatic disease SECURE Secure resources to achieve the mission

  2. GOAL 1 - ACCELERATE DISCOVERY 1 NPF Investment in Research(FY17 annual report data) NIH Investment in Psoriatic Disease Research (in Millions)(measured by fiscal year) Baseline (in thousands) Increase Number of Scientists Studying Psoriatic Disease by 50% Annual Report – 2017 Click here to view (coming soon) Patient Community Who Participates in Research More than 5,200 people have joined Citizen Pscientist and more than 222,500 questions have been answered on the site. FY18 Target (based on PubMed worldwide search of unique authors of publications related to psoriatic disease from July 1, 2017 to February 28, 2018. Total is 9,500.) 1080 researchers/month in FY 2017 1200 researchers/month in FY 2018 to date *Estimate

  3. GOAL 2 – DRAMATICALLY IMPROVE HEALTH OUTCOMES 2 30 40 60 70 Treatment Appropriate to Level of Severity (Moderate to Severe Diagnosis) Psoriasis Psoriatic Arthritis Increase Professional Memberships to 1,700 Health Care Providers(ending December 2017) Psoriatic Disease a Problem in Everyday Life (measured annually in October) Aggregate Measure of Psoriasis and Psoriatic Arthritis (measured annually in October)

  4. GOAL 3 – Secure Resources to Achieve Mission 3 Maintain 3M Operating Reserve 2016 - Calculated Reserve $1,600,000 2017 - Calculated Reserve $1,600,000 Increase Number of Volunteers to 13,200(ending June 30, 2016) Revised Volunteer Categories in 2017 10,343 9,983 9,091 February

  5. METHODOLOGY AND METRICS Goal #1 NIH Investment in Psoriatic Disease Research is published annually on the NIH website. The number we report includes all unique records with Psoriasis or Psoriatic Arthritis as a descriptor. Data on scientists studying psoriatic disease is based on PubMed search of number of unique authors (worldwide) of publications related to psoriatic disease (keywords “psoriasis” and “psoriatic arthritis” in Title/Abstract) Data on community who participates in research will based on NPF’s Citizen Pscientist initiative, which will launch in July 2015 (number of participants will be calculated regularly). Goal #2 Data for Psoriatic Disease a Problem in Everyday Life / Treatment to the Appropriate Level of Severity is based on results of NPF’s Annual Patient Panel (September). This data will be updated at the November board meeting. Professional Membership data is based on information collected in Raiser’s Edge (internal database) and includes constituents flagged as active professional members. Goal #3 Volunteer data based on information collected in Raiser’s Edge (internal database) and includes every constituent flagged with one of NPF’s defined volunteer roles. Baseline number has been revised to eliminate overlap of volunteers in multiple categories.

More Related